At-Home Flu Testing Guide
What at-home flu testing is
At-home flu testing uses a rapid antigen test to detect influenza viruses from a sample collected outside a laboratory. A sample is applied to a test cassette, and a visible result appears, usually as lines in a result window. At-home flu tests are part of the wider family of rapid antigen tests, which also covers COVID-19, RSV and other respiratory infections.
The company's infectious disease range lists influenza coverage in combo cassettes: a SARS-CoV-2 and Influenza A+B antigen combo cassette, and a wider combo that adds RSV and adenovirus. Those listings are directory-level evidence from the company's category pages. No specification table for a flu test is published on this site, because no title-consistent specification table for those products is published in the company's own material.
Single-pathogen and combo tests
Flu tests come as single-pathogen tests, which cover influenza alone, and as combo tests, which cover influenza together with other pathogens such as SARS-CoV-2. The practical difference for a buyer is what a single test run can rule in or out: a combo test gives information about more than one pathogen from one sample, while a single-pathogen test answers one question. Which format suits a market depends on local respiratory illness patterns and on what buyers in that market are asking for, and those are questions for the buyer to weigh rather than claims made here.
Sample type and collection method vary by product and are stated in the instructions that accompany a specific product. Those instructions govern any specific test, and general guidance in this guide does not replace them.
What buyers must confirm for their market
For flu tests, availability, market access and documentation vary by product and by destination market, and the company's own material states that market access is subject to written confirmation by the customer. This guide therefore makes no statement that any flu test is sold or accepted in any particular country, and buyers must confirm availability and documentation for their market in writing before ordering.
The company FAQ states that prices vary with supply and market factors, that international orders are subject to an ongoing minimum order requirement with no fixed figure published, that samples take about 7 days, and that mass production takes 20–30 days after deposit. Certificates are available upon request. Flu test results are screening indications; questions about a result belong with a healthcare professional.
Flu seasons and testing demand
Flu testing demand follows the respiratory illness season, which varies by hemisphere and by year. In temperate regions the season typically runs through the colder months, when influenza, SARS-CoV-2, RSV and other respiratory pathogens circulate together. That co-circulation is why combo tests matter: a person with respiratory symptoms could have any of several infections, and a combo test narrows the possibilities from a single sample.
For trade buyers, seasonality affects ordering more than product choice. Ordering ahead of a season, confirming lead time and availability in writing, and holding stock through the season are the practical responses to seasonal demand. The FAQ's mass-production lead time of 20–30 days after deposit is a normal-cycle figure, and buyers ordering for a season should allow for it rather than assuming rush availability.
Single-pathogen versus combo testing in practice
In practice, the choice between single-pathogen and combo flu testing depends on what the buyer's customers need to know. A clinic that needs to distinguish influenza from COVID-19 will prefer a combo test, because the two infections present similarly and the distinction affects management. A programme that only needs to know whether influenza is present may prefer a single-pathogen test for simplicity and cost.
Neither choice is universally better, and the right choice varies by setting and by season. A buyer should confirm which pathogens a specific combo covers, naming the combo product, rather than assuming that every respiratory test covers every respiratory pathogen. Availability, market access and documentation for flu tests vary by product and destination market and must be confirmed in writing before ordering.
Questions buyers should ask about any flu test
Before ordering any flu test, a buyer should be able to answer five questions in writing for the specific product. First, which pathogens does the test cover: influenza alone, or influenza together with SARS-CoV-2, RSV and adenovirus in a combo? Second, what sample type does it use, and how is the sample collected? Third, how is the result read, and what does each possible outcome mean under the product's own instructions? Fourth, what documentation accompanies the test for the destination market, and has market access been confirmed for that market? Fifth, what are the packing configurations, shelf life, instruction languages, pricing and lead time for the order?
Those five questions cover the product, its use, its documentation and its commercial terms. A supplier that answers all five in writing gives the buyer a complete basis for an order, and a supplier that answers only some of them leaves gaps that should be closed before payment. Samples, at about 7 days under the FAQ, let a buyer check the cassette, the instructions and the packing before committing to a quantity, which is especially valuable ahead of a respiratory season when timing matters.
Flu test results are screening indications from rapid antigen tests, not laboratory confirmations. A positive result supports a clinical picture that already suggests influenza, while a negative result does not exclude influenza on its own. Questions about a result belong with a healthcare professional, and this guide is written for trade buyers comparing products, not as medical guidance for individuals.
Flu testing and respiratory panels
Flu testing is increasingly bought as part of a respiratory panel rather than as a standalone test, because the symptoms of influenza overlap with those of COVID-19, RSV and other respiratory infections. A panel approach lets a single sample answer several questions at once, which matters in clinics where a patient presents with undifferentiated respiratory symptoms and the clinician needs to narrow the possibilities quickly.
For trade buyers, the panel approach changes the ordering question: instead of asking which flu test to stock, the buyer asks which respiratory panel to stock, and which pathogens that panel covers. That question should be answered naming the specific combo product, because different combos in the same family cover different pathogen sets, and a panel that omits a pathogen the buyer's market needs is a panel that fails its purpose.
Seasonal timing and stock planning
Flu test demand follows the respiratory season, which means stock planning should start before the season rather than during it. A buyer ordering for a season should confirm lead time, packing and documentation early, because a supplier that can deliver in 20 to 30 days after deposit still needs the order placed well before peak demand. Samples ordered about 7 days ahead of the main order let a buyer verify the product while the main order is still being confirmed, rather than discovering a mismatch after the season has started.